Processa Pharmaceuticals Inc
PCSA3.600USD
-0.180-4.76%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
190.31MMarket Cap
LossP/E TTM
More Details of Processa Pharmaceuticals Inc Company
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Processa Pharmaceuticals Inc Info
Ticker SymbolPCSA
Company nameProcessa Pharmaceuticals Inc
IPO dateOct 07, 2013
CEONg (George K)
Number of employees10
Security typeOrdinary Share
Fiscal year-endOct 07
Address601 21St Street, Suite 300
CityVERO BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code32960
Phone14437763133
Websitehttps://www.processapharmaceuticals.com/
Ticker SymbolPCSA
IPO dateOct 07, 2013
CEONg (George K)
Company Executives of Processa Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David Young, Ph.D.
Dr. David Young, Ph.D.
President - Research and Development, Director
President - Research and Development, Director
236.18K
+5.32%
Mr. George K. Ng
Mr. George K. Ng
Chief Executive Officer, Director
Chief Executive Officer, Director
107.20K
-28.91%
Mr. Patrick Lin
Mr. Patrick Lin
Chief Business and Strategy Officer
Chief Business and Strategy Officer
103.98K
+10.25%
Mr. Justin W. Yorke
Mr. Justin W. Yorke
Independent Chairman of the Board
Independent Chairman of the Board
53.57K
--
Dr. Sian Bigora, Pharm.D.
Dr. Sian Bigora, Pharm.D.
Chief Development Officer and Regulatory Officer, Founder
Chief Development Officer and Regulatory Officer, Founder
33.63K
+53.70%
Ms. Wendy Guy
Ms. Wendy Guy
Founder, Chief Administrative Officer
Founder, Chief Administrative Officer
26.34K
+122.14%
Ms. Geraldine Pannu
Ms. Geraldine Pannu
Independent Director
Independent Director
2.88K
--
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
1.40K
--
Mr. Russell L. Skibsted
Mr. Russell L. Skibsted
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James R. (Jim) Neal
Mr. James R. (Jim) Neal
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David Young, Ph.D.
Dr. David Young, Ph.D.
President - Research and Development, Director
President - Research and Development, Director
236.18K
+5.32%
Mr. George K. Ng
Mr. George K. Ng
Chief Executive Officer, Director
Chief Executive Officer, Director
107.20K
-28.91%
Mr. Patrick Lin
Mr. Patrick Lin
Chief Business and Strategy Officer
Chief Business and Strategy Officer
103.98K
+10.25%
Mr. Justin W. Yorke
Mr. Justin W. Yorke
Independent Chairman of the Board
Independent Chairman of the Board
53.57K
--
Dr. Sian Bigora, Pharm.D.
Dr. Sian Bigora, Pharm.D.
Chief Development Officer and Regulatory Officer, Founder
Chief Development Officer and Regulatory Officer, Founder
33.63K
+53.70%
Ms. Wendy Guy
Ms. Wendy Guy
Founder, Chief Administrative Officer
Founder, Chief Administrative Officer
26.34K
+122.14%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HX Entertainment Ltd
9.65%
Stonepine Capital Management, LLC
1.82%
Geode Capital Management, L.L.C.
0.54%
The Vanguard Group, Inc.
0.51%
Young (David)
0.42%
Other
87.07%
Shareholders
Shareholders
Proportion
HX Entertainment Ltd
9.65%
Stonepine Capital Management, LLC
1.82%
Geode Capital Management, L.L.C.
0.54%
The Vanguard Group, Inc.
0.51%
Young (David)
0.42%
Other
87.07%
Shareholder Types
Shareholders
Proportion
Corporation
9.72%
Investment Advisor/Hedge Fund
2.38%
Individual Investor
1.01%
Investment Advisor
0.53%
Research Firm
0.17%
Hedge Fund
0.07%
Other
86.12%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
40
635.57K
1.12%
+302.79K
2025Q2
48
5.43M
20.63%
+4.60M
2025Q1
51
708.86K
10.77%
+202.96K
2024Q4
53
384.33K
11.96%
-82.26K
2024Q3
54
333.95K
11.36%
-132.80K
2024Q2
56
390.99K
14.35%
-120.98K
2024Q1
59
435.26K
19.04%
+41.69K
2023Q4
57
343.21K
27.89%
+52.02K
2023Q3
57
335.15K
27.25%
+38.59K
2023Q2
52
272.47K
22.21%
-24.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HX Entertainment Ltd
5.47M
10.86%
+5.47M
--
Aug 05, 2025
Geode Capital Management, L.L.C.
50.57K
0.1%
+16.16K
+46.96%
Jun 30, 2025
The Vanguard Group, Inc.
24.43K
0.05%
--
--
Jun 30, 2025
Young (David)
236.18K
0.47%
+11.93K
+5.32%
Aug 07, 2025
Ng (George K)
107.20K
0.21%
-43.60K
-28.91%
Aug 07, 2025
Lin (Patrick)
103.98K
0.21%
+9.67K
+10.25%
Aug 07, 2025
Yorke (Justin W)
53.57K
0.11%
--
--
Aug 07, 2025
CorLyst, L.L.C.
41.46K
0.08%
--
--
Aug 07, 2025
Virtu Americas LLC
104.72K
0.21%
+61.49K
+142.25%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 15, 2025
Merger
25→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Date
Type
Ratio
Dec 15, 2025
Merger
25→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
Jan 18, 2024
Merger
20→1
FAQs
Who are the top five shareholders of Processa Pharmaceuticals Inc?
The top five shareholders of Processa Pharmaceuticals Inc are:
HX Entertainment Ltd holds 5.47M shares, accounting for 10.86% of the total shares.
Geode Capital Management, L.L.C. holds 50.57K shares, accounting for 0.10% of the total shares.
The Vanguard Group, Inc. holds 24.43K shares, accounting for 0.05% of the total shares.
Young (David) holds 236.18K shares, accounting for 0.47% of the total shares.
Ng (George K) holds 107.20K shares, accounting for 0.21% of the total shares.
HX Entertainment Ltd holds 5.47M shares, accounting for 10.86% of the total shares.
Geode Capital Management, L.L.C. holds 50.57K shares, accounting for 0.10% of the total shares.
The Vanguard Group, Inc. holds 24.43K shares, accounting for 0.05% of the total shares.
Young (David) holds 236.18K shares, accounting for 0.47% of the total shares.
Ng (George K) holds 107.20K shares, accounting for 0.21% of the total shares.
What are the top three shareholder types of Processa Pharmaceuticals Inc?
The top three shareholder types of Processa Pharmaceuticals Inc are:
HX Entertainment Ltd
Stonepine Capital Management, LLC
Geode Capital Management, L.L.C.
HX Entertainment Ltd
Stonepine Capital Management, LLC
Geode Capital Management, L.L.C.
How many institutions hold shares of Processa Pharmaceuticals Inc (PCSA)?
As of 2025Q3, 40 institutions hold shares of Processa Pharmaceuticals Inc, with a combined market value of approximately 635.57K, accounting for 1.12% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -19.51%.
What is the biggest source of revenue for Processa Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Processa Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
